Trials / Unknown
UnknownNCT04984369
The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment
An Open, Multicenter Phase II Clinical Study to Evaluate Safety and Efficacy of HLX208 (BRAF V600E Inhibitor) Combined With Cetuximab in Patients With Metastatic Colorectal Cancer (mCRC)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Shanghai Henlius Biotech · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An open, multicenter phase II clinical study to evaluate safety and efficacy of HLX208 (BRAF V600E inhibitor) combined with cetuximab for metastatic colorectal cancer (mCRC) with BRAF V600E Mutation after first-line treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HLX208 | HLX208 450mg bid po OR 600mg bid po OR 900mg bid po |
| DRUG | Cetuximab Injection [Erbitux] | Cetuximab 500 mg/m2 IV Q2W |
Timeline
- Start date
- 2021-08-11
- Primary completion
- 2024-06-15
- Completion
- 2025-01-15
- First posted
- 2021-07-30
- Last updated
- 2023-08-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04984369. Inclusion in this directory is not an endorsement.